Stocksigma LogoStocksigma Logo

Viyash Scientific Reports Strong H1 FY27 Growth with Expanding Formulations and Deleveraging

Viyash Scientific posted H1 FY27 revenue of ₹19,343 Mn, up 17.8% YoY, with pre-ESOP EBITDA rising 29.9% YoY to ₹4,124 Mn and margin expanding 200 bps to

Viyash Scientific Reports Strong H1 FY27 Growth with Expanding Formulations and Deleveraging

Sequent Scientific Ltd · Investor Presentation · 14 Nov 2026, 12:11 am

Viyash Scientific Reports Strong H1 FY27 Growth with Expanding Formulations and Deleveraging Viyash Scientific posted H1 FY27 revenue of ₹19,343 Mn, up 17.8% YoY, with pre-ESOP EBITDA rising 29.9% YoY to ₹4,124 Mn and margin expanding 200 bps to 21.3%. H1 PAT reached ₹1,639 Mn, up 49.4% YoY. Net debt fell sharply to ₹261 Mn (0.0x EBITDA). Formulations grew 26% YoY in H1 to ₹11,134 Mn, while APIs rose 8% to ₹7,987 Mn. Key strategic developments include completing the BioForLife Italy acquisition on 1st Oct'26, expanding API capacity by 128 KL in Nalgonda, and building oncology R&D capabilities.

Original exchange filing (PDF)

More announcements from Sequent Scientific Ltd

All Sequent Scientific Ltd announcements